Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT
Standard
Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT. / Nagler, Arnon; Ngoya, Maud; Galimard, Jacques-Emmanuel; Labopin, Myriam; Kröger, Nicolaus; Socié, Gerard; Gedde-Dahl, Tobias; Potter, Victoria; Schroeder, Thomas; Platzbecker, Uwe; Ganser, Arnold; Blaise, Didier; Salmenniemi, Urpu; Maertens, Johan; Craddock, Charles; Labussière-Wallet, Hélène; Yakoub-Agha, Ibrahim; Savani, Bipin; Mohty, Mohamad.
In: BONE MARROW TRANSPL, Vol. 57, No. 12, 12.2022, p. 1788-1796.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT
AU - Nagler, Arnon
AU - Ngoya, Maud
AU - Galimard, Jacques-Emmanuel
AU - Labopin, Myriam
AU - Kröger, Nicolaus
AU - Socié, Gerard
AU - Gedde-Dahl, Tobias
AU - Potter, Victoria
AU - Schroeder, Thomas
AU - Platzbecker, Uwe
AU - Ganser, Arnold
AU - Blaise, Didier
AU - Salmenniemi, Urpu
AU - Maertens, Johan
AU - Craddock, Charles
AU - Labussière-Wallet, Hélène
AU - Yakoub-Agha, Ibrahim
AU - Savani, Bipin
AU - Mohty, Mohamad
N1 - © 2022. The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/12
Y1 - 2022/12
N2 - Trends in outcome of transplantation (HSCT) in secondary acute myeloid leukemia (sAML) are limited. We evaluated results of HSCT in 4224 patients with sAML in complete remission; 1337 were transplanted in 2000-2010 and 2887 in 2011-2020. Median age was 54 (range, 18-74) and 59 (range, 18-78) years, respectively (p < 0.0001). Donors were MSD in 65% vs. 37%, 10/10 UD in 27% vs. 50%, and 9/10 UD in 8% vs. 13%, respectively (p < 0.0001). Conditioning was myeloablative in 46% and 38%, respectively. Two-year non-relapse mortality (NRM) was lower in patients transplanted in 2011-2020 vs. those transplanted in 2000-2010, 18% vs. 21% (hazard ratio (HR) = 0.82, 95% CI: 0.68-0.9; p = 0.04) and modified GVHD-free, relapse-free survival (GRFS) (HR = 0.9, 95% CI: 0.81-0.99; p = 0.04) was better in patients transplanted in the 2011-2020 vs. those transplanted in 2000-2010. Two-year relapse incidence (RI) was similar between the 2 groups with 32% vs. 31%, (HR = 1.05, 95% CI: 0.9-1.22; p = 0.55). Likewise, leukemia-free survival (LFS) (HR = 0.95, 95% CI: 0.84-1.07; p = 0.38) and overall survival (OS) (HR = 0.93, 95% CI: 0.82-1.05; p = 0.26) were not significantly different between the two periods. In conclusion, Incidence of NRM has been significantly reduced and GRFS significantly increased in HSCT for sAML in the last 2 decades.
AB - Trends in outcome of transplantation (HSCT) in secondary acute myeloid leukemia (sAML) are limited. We evaluated results of HSCT in 4224 patients with sAML in complete remission; 1337 were transplanted in 2000-2010 and 2887 in 2011-2020. Median age was 54 (range, 18-74) and 59 (range, 18-78) years, respectively (p < 0.0001). Donors were MSD in 65% vs. 37%, 10/10 UD in 27% vs. 50%, and 9/10 UD in 8% vs. 13%, respectively (p < 0.0001). Conditioning was myeloablative in 46% and 38%, respectively. Two-year non-relapse mortality (NRM) was lower in patients transplanted in 2011-2020 vs. those transplanted in 2000-2010, 18% vs. 21% (hazard ratio (HR) = 0.82, 95% CI: 0.68-0.9; p = 0.04) and modified GVHD-free, relapse-free survival (GRFS) (HR = 0.9, 95% CI: 0.81-0.99; p = 0.04) was better in patients transplanted in the 2011-2020 vs. those transplanted in 2000-2010. Two-year relapse incidence (RI) was similar between the 2 groups with 32% vs. 31%, (HR = 1.05, 95% CI: 0.9-1.22; p = 0.55). Likewise, leukemia-free survival (LFS) (HR = 0.95, 95% CI: 0.84-1.07; p = 0.38) and overall survival (OS) (HR = 0.93, 95% CI: 0.82-1.05; p = 0.26) were not significantly different between the two periods. In conclusion, Incidence of NRM has been significantly reduced and GRFS significantly increased in HSCT for sAML in the last 2 decades.
KW - Humans
KW - Middle Aged
KW - Hematopoietic Stem Cell Transplantation/methods
KW - Leukemia, Myeloid, Acute
KW - Transplantation Conditioning/methods
KW - Neoplasms, Second Primary/etiology
KW - Remission Induction
KW - Recurrence
KW - Retrospective Studies
KW - Graft vs Host Disease/etiology
U2 - 10.1038/s41409-022-01825-0
DO - 10.1038/s41409-022-01825-0
M3 - SCORING: Journal article
C2 - 36114249
VL - 57
SP - 1788
EP - 1796
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 12
ER -